HRP20030247A2 - New thiadiazoles and oxadiazoles and their use asphosphodiesterase-7 inhibitors - Google Patents

New thiadiazoles and oxadiazoles and their use asphosphodiesterase-7 inhibitors Download PDF

Info

Publication number
HRP20030247A2
HRP20030247A2 HR20030247A HRP20030247A HRP20030247A2 HR P20030247 A2 HRP20030247 A2 HR P20030247A2 HR 20030247 A HR20030247 A HR 20030247A HR P20030247 A HRP20030247 A HR P20030247A HR P20030247 A2 HRP20030247 A2 HR P20030247A2
Authority
HR
Croatia
Prior art keywords
methyl
thiadiazol
dihydro
phenyl
cyclohexylimino
Prior art date
Application number
HR20030247A
Other languages
English (en)
Croatian (hr)
Inventor
Vergne Fabrice
Ducrot Pierre
Andrianjara Charles
Bernardelli Patrick
Lorthiois Edwige
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HRP20030247A2 publication Critical patent/HRP20030247A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HR20030247A 2000-10-02 2003-04-01 New thiadiazoles and oxadiazoles and their use asphosphodiesterase-7 inhibitors HRP20030247A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402710A EP1193261A1 (en) 2000-10-02 2000-10-02 New thiadiazoles and their use as phosphodiesterase-7 inhibitors
PCT/EP2001/011330 WO2002028847A1 (en) 2000-10-02 2001-10-01 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
HRP20030247A2 true HRP20030247A2 (en) 2005-04-30

Family

ID=8173891

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030247A HRP20030247A2 (en) 2000-10-02 2003-04-01 New thiadiazoles and oxadiazoles and their use asphosphodiesterase-7 inhibitors

Country Status (43)

Country Link
US (1) US7122565B2 (is)
EP (2) EP1193261A1 (is)
JP (1) JP4177098B2 (is)
KR (1) KR100614158B1 (is)
CN (1) CN1639141A (is)
AP (1) AP1541A (is)
AR (1) AR035347A1 (is)
AT (1) ATE304003T1 (is)
AU (2) AU2001289945B2 (is)
BG (1) BG107654A (is)
BR (1) BR0114391A (is)
CA (1) CA2424279A1 (is)
CZ (1) CZ2003857A3 (is)
DE (1) DE60113283T2 (is)
DK (1) DK1326853T3 (is)
DZ (1) DZ3440A1 (is)
EA (1) EA007179B1 (is)
EC (1) ECSP034534A (is)
EE (1) EE200300134A (is)
ES (1) ES2247166T3 (is)
GE (1) GEP20053459B (is)
GT (1) GT200100196A (is)
HN (1) HN2001000217A (is)
HR (1) HRP20030247A2 (is)
HU (1) HUP0301248A3 (is)
IL (1) IL155122A0 (is)
IS (1) IS6759A (is)
MA (1) MA25916A1 (is)
MX (1) MXPA03002839A (is)
NO (1) NO20031482D0 (is)
NZ (1) NZ524852A (is)
OA (1) OA12518A (is)
PA (1) PA8529501A1 (is)
PE (1) PE20020419A1 (is)
PL (1) PL366332A1 (is)
PT (1) PT1326853E (is)
SI (1) SI1326853T1 (is)
SK (1) SK3812003A3 (is)
SV (1) SV2003000633A (is)
TN (1) TNSN01139A1 (is)
WO (1) WO2002028847A1 (is)
YU (1) YU24503A (is)
ZA (1) ZA200302346B (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1597385A1 (en) * 2002-11-13 2005-11-23 Bayer HealthCare AG DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7A1 (PDE7a1)
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
JP2006219373A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体
JP2006219374A (ja) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pde7阻害作用を有するイミダゾトリアジノン誘導体
MX2007000214A (es) 2004-07-01 2007-05-10 Asubio Pharma Co Ltd Derivado de tienopirazol que tiene actividad inhibidora de pde 7.
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス,インコーポレイティド Pde阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド 5ht受容体介在性の神経新生
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
MX2009010450A (es) 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MD3995C2 (ro) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Utilizare a di(µ-Ofenoxi)-di{[2-(4-aminobenzensulfamido)-5-etil-1,3,4-tiadiazol]-3,5-dibromosalicilidentiosemicarbazonato(-1)-cupru} în calitate de inhibitor al proliferării celulelor T-47D ale cancerului mamar
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
KR20220047894A (ko) 2010-11-08 2022-04-19 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN102276625B (zh) * 2011-08-24 2013-07-17 天津药物研究院 噻二唑衍生物
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CN103288777A (zh) * 2013-05-28 2013-09-11 浙江禾田化工有限公司 特丁噻草隆关键中间体2-甲基氨基-5-叔丁基-1,3,4-噻二唑的合成方法
US9416652B2 (en) 2013-08-08 2016-08-16 Vetco Gray Inc. Sensing magnetized portions of a wellhead system to monitor fatigue loading
CA2987876A1 (en) * 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CN107674042B (zh) * 2017-09-28 2020-09-25 河南科技大学 一种超声波无溶剂合成噻二唑类化合物的方法
CN113480486B (zh) * 2021-07-30 2022-05-24 赣南师范大学 一种3-胺基-1,2,4-三唑类衍生物及其制备方法和应用
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE251979C (is)
FR2388806A1 (fr) 1977-04-25 1978-11-24 Gulf Oil Corp Nouvelles 3-benzyl-2-methylimino-5-phenyl4-1,3,4 thiadiazolines et leur application au desherbage chimique de cultures
DK270880A (da) 1979-07-09 1981-01-10 Gulf Oil Corp Phenyliminothiadiazolidiner deres fremstilling og anvendelse i plantevaekstregulerende midler
DD247003A1 (de) * 1985-11-07 1987-06-24 Hydrierwerk Rodleben Veb Verfahren zur herstellung von in 2-stellung mit amninhaltigen gruppen subst. 7 h-1,3,4-thiadiazolo(3,2-a)pyrimidinen
DD251979A1 (de) * 1986-08-01 1987-12-02 Neubauer T Paedagog Hochschule Verfahren zur herstellung von s-triazinylsubstituierten 2-imino-1,3,4-oxadiazolinen
DE4418066A1 (de) 1994-05-24 1995-11-30 Bayer Ag Substituierte Thiadiazoline
EP1054669B9 (en) * 1998-02-17 2004-09-15 Boehringer Mannheim Gmbh Use of thiadiazolo[4,3-a]pyridine derivatives

Also Published As

Publication number Publication date
EE200300134A (et) 2003-08-15
EP1193261A1 (en) 2002-04-03
ZA200302346B (en) 2004-08-04
CZ2003857A3 (cs) 2004-02-18
KR100614158B1 (ko) 2006-08-21
ECSP034534A (es) 2003-07-25
GEP20053459B (en) 2005-02-25
GT200100196A (es) 2002-07-18
DE60113283D1 (de) 2005-10-13
US7122565B2 (en) 2006-10-17
EP1326853B1 (en) 2005-09-07
BR0114391A (pt) 2003-06-24
PE20020419A1 (es) 2002-07-18
CA2424279A1 (en) 2002-04-11
PL366332A1 (en) 2005-01-24
MA25916A1 (fr) 2003-10-01
JP2004510769A (ja) 2004-04-08
ATE304003T1 (de) 2005-09-15
NO20031482L (no) 2003-04-01
HUP0301248A3 (en) 2005-06-28
EP1326853A1 (en) 2003-07-16
DZ3440A1 (fr) 2002-04-11
EA200300333A1 (ru) 2003-10-30
HN2001000217A (es) 2002-06-13
IL155122A0 (en) 2003-10-31
DK1326853T3 (da) 2005-12-12
CN1639141A (zh) 2005-07-13
IS6759A (is) 2003-03-27
WO2002028847A1 (en) 2002-04-11
DE60113283T2 (de) 2006-06-08
AP2003002764A0 (en) 2003-03-31
KR20030068542A (ko) 2003-08-21
YU24503A (sh) 2006-03-03
HUP0301248A2 (hu) 2003-10-28
AU8994501A (en) 2002-04-15
PT1326853E (pt) 2005-11-30
NO20031482D0 (no) 2003-04-01
SK3812003A3 (en) 2004-05-04
MXPA03002839A (es) 2004-09-10
SI1326853T1 (sl) 2005-12-31
AR035347A1 (es) 2004-05-12
AU2001289945B2 (en) 2005-12-22
ES2247166T3 (es) 2006-03-01
TNSN01139A1 (en) 2005-11-10
PA8529501A1 (es) 2003-06-30
BG107654A (bg) 2003-12-31
OA12518A (en) 2006-05-29
AP1541A (en) 2006-01-11
EA007179B1 (ru) 2006-08-25
JP4177098B2 (ja) 2008-11-05
SV2003000633A (es) 2003-04-03
NZ524852A (en) 2004-09-24
US20030045557A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
EP1326853B1 (en) Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
AU2001289945A1 (en) New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
AU2019364336B2 (en) TYK2 inhibitors and uses thereof
US7141596B2 (en) Inhibitors of proteins that bind phosphorylated molecules
CA2564638A1 (en) Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders
JP5670731B2 (ja) ある種の化学物質、組成物、および方法
US20060229336A1 (en) Ccr5 antagonists as therapeutic agents
US20070049558A1 (en) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
KR102679766B1 (ko) 피라졸 magl 저해제
AU2014209315A1 (en) Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
AU2010217606A1 (en) Compounds as bradykinin B1 antagonists
CA2066696A1 (en) Substituted urea compounds and their preparation and use
AU2004215658B2 (en) Novel diazabicyclic aryl derivatives
TW202346280A (zh) 雙重magl及faah抑制劑
WO2022155111A1 (en) Indole derivatives as kinase inhibitors
RU2338746C2 (ru) Новые диазабициклические арильные производные, содержащие их фармацевтические композиции и их применение
EA040206B1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn

Legal Events

Date Code Title Description
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
A1OB Publication of a patent application
OBST Application withdrawn